CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

  • K. Sakakibara, N. Saito, T. Sato, A. Suzuki, Y. Hasegawa, J. M. Friedman, D. W. Kufe, D. D. VonHoff, T. Iwami, T. Kawabe
  • Blood, August 2011, American Society of Hematology
  • DOI: 10.1182/blood-2011-01-333138

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Jonathan Malcolm Friedman